Study study type PathologyT1T0Patientssample sizesROB Results

mHNSCC - L2 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - all population

versus Standard of Care (SoC)
durvalumab alone
EAGLE (D vs ICC), 2019
  NCT02369874
RCTmHNSCC - L2 - all populationdurvalumabinvestigator’s choice: cetuximab, taxane, methotrexate, or fluoropyrimidine-based regimenpatients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).of the oral cavity, oropharynx, hypopharynx, or larynx not amenable to curative therapy who had progression or recurrence during or after only one systemic treatment regimen containing a platinum agent240 / 249some concern
inconclusive
  • inconclusive 12 % decrease in deaths (OS) (PE)
nivolumab alone
CheckMate 141, 2016
  NCT02105636
RCTmHNSCC - L2 - all populationnivolumabICC (methotrexate, docetaxel or cetuximab)patients with recurrent squamous-cell carcinoma of the head and neck whose disease had progressed within 6 months after platinum-based chemotherapy240 / 121some concern
conclusif
  • demonstrated 30 % decrease in deaths (OS) (PE)
  • suggested 32 % decrease in deaths (OS) (extension)
pembrolizumab alone
KEYNOTE-040 (all population), 2018
  NCT02252042
RCTmHNSCC - L2 - all populationpembrolizumabchemotherapy (methotrexate, docetaxel or cetuximab)patients with recurrent or metastatic head and neck squamous cell cancer that progressed during or after platinum-containing treatment : all population247 / 248some concern
conclusif
  • demonstrated 20 % decrease in deaths (OS) (PE)

mHNSCC - L2 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 positive

versus Standard of Care (SoC)
pembrolizumab alone
KEYNOTE-040 (CPS >1), 2018
  NCT02252042
RCTmHNSCC - L2 - PDL1 positivepembrolizumabchemotherapy (methotrexate, docetaxel or cetuximab)patients with recurrent or metastatic head and neck squamous cell cancer that progressed during or after platinum-containing treatment : only patients with CPS > 1196 / 191some concern
conclusif
  • demonstrated 26 % decrease in deaths (OS) (PE)